Review paper

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development

Volume: 10, Issue: 2, Pages: 196 - 201
Published: Sep 17, 2018
Abstract
Today, glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists are established glucose‐lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia. GLP ‐1 was shown to target these defects, and after the discovery that dipeptidyl peptidase‐4 inactivates native...
Paper Details
Title
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Published Date
Sep 17, 2018
Volume
10
Issue
2
Pages
196 - 201
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.